Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.